Indapta harnesses natural NK cell subset to create allogeneic cancer therapy

Indapta streamlines universal allogeneic NK cell development by forgoing genetic engineering

Indapta is sidestepping genome engineering for its universal NK cells, a strategy that not only reduces manufacturing costs but also broadens the number of cancer patients it could treat relative to genetically edited allogeneic NK cell therapies.

Indapta Therapeutics Inc. was founded in 2017 based on IP covering the use of unedited FCER1G-deficient NK, or “G-NK,” cells plus at least one antitumor antibody recognized by CD16 to kill cancer cells. Indapta licensed the IP from Michigan State University, where co-founder Sungjin Kim was an assistant professor. Kim is

Read the full 881 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers